Understanding the Cellular Basis for Altered Cognition in Schizophrenia

Guest: Aaron Miller, MD Early real-world experience with the 2024 McDonald criteria suggests a meaningful increase in multiple sclerosis (MS) diagnoses, driven largely by recognition of optic nerve involvement and reclassification of radiologically isolated syndrome. Hear from Dr. Aaron Miller as he reviews emerging evidence, explains how these updates are reshaping diagnostic pathways, and addresses practical challenges in implementation. Dr. Miller is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York. He also spoke about this topic at the 2026 American Academy of Neurology (AAN) Annual Meeting.

Guest: Riley Bove, MD, MMSc Multiple sclerosis (MS) is often diagnosed during peak reproductive years, making proactive, informed care essential across the lifespan. Hear from Dr. Riley Bove as she discusses the importance of early, ongoing conversations about fertility, pregnancy, and menopause in this population. Dr. Bove is an Associate Professor at UCSF Weill Institute for Neurosciences, and she discussed this topic at the 2026 American Academy of Neurology (AAN) Annual Meeting.

Guest: Elizabeth Wilson, MD At the 2026 American Academy of Neurology (AAN) Annual Meeting, experts are sharing the latest developments in pediatric multiple sclerosis (MS). Dr. Elizabeth Wilson is here to share insights on how new adult MS research, neuro-ophthalmology collaboration, and emerging clinical data are shaping the future of care. Dr. Wilson is the Director of the Multiple Sclerosis and Neuroimmunology Center at Cincinnati Children's Hospital.

Guest: Aaron Miller, MD Hear from Dr. Aaron Miller as he shares important updates in multiple sclerosis (MS) at the 2026 American Academy of Neurology (AAN) Annual Meeting. Dr. Miller is the Medical Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis and a Professor of Neurology at the Icahn School of Medicine at Mount Sinai in New York.

Guest: Adil Harroud, MD Guest: Dylan Hamitouche Host: Ryan Quigley Multimodal aging signatures are reshaping our understanding of progression and prognosis in multiple sclerosis (MS). Host Ryan Quigley sits down with Dr. Adil Harroud and Mr. Dylan Hamitouche to learn more about implications for the future of risk stratification and personalized treatment in MS, a topic they presented on at the 2026 ACTRIMS Forum. Dr. Harroud is a neurologist and the co-leader of the Neuroimmunology Diseases Research Group at the Montreal Neurological Institute at McGill University. Mr. Hamitouche is a medical student at McGill University.

Guest: Jennifer Yang, MD Emerging evidence shows that children with multiple sclerosis exhibit accelerated biological aging. Learn more about the potential implications with Dr. Jennifer Yang, who spoke about this topic at the 2026 ACTRIMS Forum. She's an Assistant Professor of Neurosciences at the UC San Diego School of Medicine and the Division of Pediatric Neurology at Rady Children's Hospital.

Guest: Raphael Schneider, MD, PhD, FRCPC, CIP Multiplex proteomic biomarker panels are redefining how we understand and monitor multiple sclerosis (MS) by capturing interconnected pathways in a single sample. Hear from Dr. Raphael Schneider as he explores how these tools could inform prognosis, risk stratification, and clinical trial design, which he spoke about at the 2026 ACTRIMS Forum. Dr. Schneider is a neurologist and researcher at the BARLO MS Centre at St. Michael’s Hospital as well as an Assistant Professor and the Elizabeth S. Barford Early Career Professor in Multiple Sclerosis in the Department of Medicine at the University of Toronto.

Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Michael Salvatore, PhD Guest: Vicki Nejtek-Salvatore, PhD Translational research is reshaping the way we understand, detect, and manage Parkinson’s disease. To learn more about how current research efforts are uncovering early biomarkers and redefining intervention strategies, Dr. Jerome Lisk sits down with Dr. Michael Salvatore and Dr. Vicki Nejtek-Salvatore, professors at University of North Texas Health Science Center in Fort Worth and co-founders of the Parkinson Discovery Institute in Fort Worth, Texas.

Guest: Ashvini Keshavan, MRCP, PhD Very few patients in UK memory services receive an Alzheimer’s diagnosis supported by molecular testing, limiting timely access to emerging therapies. The ADAPT trial—which was funded by the Blood Biomarker Challenge, a multi-million-pound program supported by the Alzheimer's Society, Alzheimer's Research UK, and players of People's Postcode Lottery—aims to close this gap by evaluating the real-world integration of blood-based biomarkers into standard NHS memory care pathways. Join Dr. Ashvini Keshavan as she discusses how this approach may impact diagnostic accuracy, treatment access, and healthcare resource use across the UK. Dr. Keshavan is a Senior Clinical Research Fellow and Honorary Consultant Neurologist specializing in Alzheimer’s disease biomarkers at the University College London, and this topic was presented as a poster at the 2025 CTAD conference.

Guest: Le Hua, MD Diagnosing multiple sclerosis (MS) in older patients presents unique challenges, especially as age-related comorbidities and common neurological findings often mimic MS. Hear from Dr. Le Hua as she highlights the importance of thorough clinical history, cautious interpretation of imaging, and the role of paraclinical studies in ensuring accurate MS diagnosis, particularly in patients over 50. Dr. Hua is the Director of Clinical Operations and Director of the Multiple Sclerosis Program at the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas. She also spoke about this topic at the 2025 European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Congress.